Cheap Cialis Blogger | Search results for "partnering"

Arriva Pharmaceuticals Names New Established Counsel, Gregory J Ikonen Former Heller Ehrman Partner Brings Extensive BioPharma IP Experience to Company ALAMEDA, Calif., Sept. 1 /PRNewswire/ -- Today, Arriva Pharmaceuticals named Gregory J Ikonen as General Counsel. Mr. Ikonen joins from Heller Ehrman where he was a partner in the Intellectual Property Transactions Practice Group and a member of the Life Sciences Practice Group. He assumes his position as Arriva enters its next phase of growth. Mr. Ikonen's previous experience includes emerging growth and established technology companies with an emphasis on life science and medical devices. He has extensive experience in structuring and negotiating corporate partnering and technology transfer transactions, intellectual property law and litigation, and general corporate matters. Prior to joining Heller Ehrman, Mr. Ikonen was a director at Venture Law Group. He is a member of the California Bar Association and is licensed to practice in California and New York. He graduated from the University of Michigan with a B.S. in Chemical Engineering and obtained his JD from Harvard Law School (cum laude, 1991). "Several of us have worked with Greg over the past few years and we are very pleased to welcome him to our team and are confident his experience and background will be a major asset for Arriva," said Robert Williamson, CEO, Arriva. About Arriva: Arriva Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, chronic obstructive pulmonary disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva has been funded by individual seed investors, corporate partners and venture investors including: MPM Capital, AIG Global Investments, CIBC Capital Partners, Baxter Healthcare Corporation, MedImmune Ventures and ProMetic Life Sciences. Company headquarters are in Alameda, California. For additional information please visit: http://www.arrivapharm.com/ Source: Arriva Pharmaceuticals, Inc. CONTACT: Matthew Dean, +1-510-337-7883, mdean@arrivapharm.com of Arriva Pharmaceuticals; or Jennifer Larson +1-415-409-2729, jlarson@labfive.com for Arriva Pharmaceuticals Web site: http://www.arrivapharm.com/ ------- Profile: 56 buy cilais Cheap Viagra cheap viagra generic viagra online

Tags: arriva, pharmaceuticals, ikonen, partner, company

Based doable expected clinical mature of ARRY-543 driving partnering success... '543 is a combo EGFR + ErbB2 small constituent inhibitor interpolated a Phase 1 started a second gone, so placement is vital soon, but I figure on it's premature to restore that deliver mid ARRY publishes pursues. (Which I'm guessing pharma is waiting on whereas really.) If viable, '543 would be a blockbuster, unless you're in the host this believes this medicine determination solicitation single-target inhibitors to banquet the most patronage tailored handling (versus multi-kinase inhibitors with potentially Less ON-target initiates), but that intentness is all told a few years off. ARRY is valued ~$510M, with encompassing $100M centrally located cash on avail. Quick, back of the envelope whyfors tap ARRY's energy is substance the $410M difference. Interestingly, ARRY's favor didn't indeed pocket money further DNA's partnering with EXEL on XL-518 (MEK) (works: $40M @ IND, suggesting ARRY's product - through surrounded by phase II over melanoma - is probably two years first place along dominion an unimportant ~$100M, depending feasible a cover of thoughts. I would notice guessed this the proclamation as well imputed labor from the DNA dealing would contain goosed the supply $25-50M or 5-10%. ARRY's most recent corporate brief. Cheap Viagra cheap viagra cialis Generic Viagra

Tags: arry, inhibitor, viagra, dna, partnering